Pharmaceutical composition comprising a combination of (i) at least two different biocompatible nanoparticles and (ii) at least one Compound of interestTypically at least a Pharmaceutical Compound, administered to a subject in need of such at least one Compound of interestWhere at least two different biocompatible nanoparticles enhance the effectiveness of the compounds of interest.The at least two biocompatible nanoparticles can be administered simultaneously or sequentially to the subject but are managed separately.Typically with an interval of more than approximately 5 minutes and approximately 72 hours, at least one Compound of interestPreferably at least before Administration of a compound of interest in that subject.The Longest dimension of at least two biocompatible nanoparticles is typically between about 4 nm and 500 nm.The value of load on the surface of a First Absolute biocompatible nanoparticle is at least 10 mV and load value in all of the second surface or biocompatible nanoparticle cuAny additional biocompatible nanoparticle has a difference of at least 10 mV with the load value in all of the first biocompatible nanoparticle Surface.Claim 5: the pharmaceutical composition according to claim 4, wherein the at least two different nanoparticles selected Lipid based nanoparticles.Protein based Nanoparticles, polymeric Nanoparticles, nanoparticles based copolymers Nanoparticles, Carbon BasedViral nanoparticles and any mixture of them.Claim 6: the pharmaceutical composition according to any one of claims 1 to 3,Where at least two different inorganic nanoparticles and nanoparticles are the longest dimension of each of these nanoparticles is below approximately 7 nm.Claim 8: the pharmaceutical composition according to claim 7, wherein the inorganic material is selected from Calcium Carbonate, Magnesium carbonate (caco\u2083) (mgco\u2083)Magnesium Hydroxide (mg (OH) \u2082), iron hydroxide (Fe (OH) \u2082 oxihidr\u00f3xido), Iron (FeOOH), iron oxide (fe\u20
